Xin Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Xin Xu has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Jianxing He
Department of Thoracic Oncology and Surgery, China State Key Laboratory of Respiratory Disease and National Clinical Research Center for Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China
3 shared publications - Chao Yang
Department of Blood Transfusion, The General Hospital of the PLA Rocket Force, Beijing, China
2 shared publications Guilin Peng
Department of Thoracic Surgery and Organ Transplantation, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
2 shared publications- Weixue Cui
Department of Thoracic Surgery/Oncology, First Affiliated Hospital of Guangzhou Medical University, China State Key Laboratory of Respiratory Disease and National Clinical Research Center for Respiratory Disease, Guangzhou 510120, China
2 shared publications - Abdul Basit
Vascular Biology and Therapeutics Program, Yale University School of Medicine, New Haven, CT 06520, USA
1 shared publication - Andrew Kuo
Vascular Biology Program, Boston Children’s Hospital, and Department of Surgery, Harvard Medical School
1 shared publication
Latest Publications
- 28 April 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 13 (591)
Pazopanib ameliorates acute lung injuries via inhibition of MAP3K2 and MAP3K3
MAP3K inhibition attenuates acute lung injuries in mice and reduced edema in lung transplantation recipients.
- 28 April 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 13 (591)
Pazopanib ameliorates acute lung injuries via inhibition of MAP3K2 and MAP3K3
MAP3K inhibition attenuates acute lung injuries in mice and reduced edema in lung transplantation recipients.
- Open Access
- 1 March 2021
- Published by AME Publishing Company in Translational Lung Cancer Research
- Vol. 10 (3) , 1588-1593
Pulmonary fibrosis combined with lung cancer following lung transplantation: should we do more?
Currently, lung transplantation is the standard of care for patients with end-stage lung disease, with interstitial lung disease (ILD) being the most common reason in the recent years In the other hand, in cases where stage II and III lung cancer have been identified following lung transplantation, long-term survival outcomes are poor when compared to lung cancer patients that have not received a lung transplant because the use of immunosuppressant and the problem of rejection and infection and the treatment of recurrence and so on. However, there is no statistical difference observed in stage I (pT1N0M0) patients. In this paper we report about a patient with ILD receiving left lung transplantation in the early time. A lesion of the right lung which was considered the normal ILD tissue and without enough attention. Post-transplant it showed progress and finally the whole right lung (native lung) was occupied by the tumor. Some ground glass changes could also be found in the transplanted lung several months later. A secondary lung transplant was performed for this patient, and there has been no postoperative recurrence thus far. For lung transplant patients with high-risk factors, effective surveillance methods are required for the early detection of lung cancer.
- 1 March 2021
- Published by AME Publishing Company in Translational Lung Cancer Research
- Vol. 10 (3) , 1588-1593
Open AccessPulmonary fibrosis combined with lung cancer following lung transplantation: should we do more?
Currently, lung transplantation is the standard of care for patients with end-stage lung disease, with interstitial lung disease (ILD) being the most common reason in the recent years In the other hand, in cases where stage II and III lung cancer have been identified following lung transplantation, long-term survival outcomes are poor when compared to lung cancer patients that have not received a lung transplant because the use of immunosuppressant and the problem of rejection and infection and the treatment of recurrence and so on. However, there is no statistical difference observed in stage I (pT1N0M0) patients. In this paper we report about a patient with ILD receiving left lung transplantation in the early time. A lesion of the right lung which was considered the normal ILD tissue and without enough attention. Post-transplant it showed progress and finally the whole right lung (native lung) was occupied by the tumor. Some ground glass changes could also be found in the transplanted lung several months later. A secondary lung transplant was performed for this patient, and there has been no postoperative recurrence thus far. For lung transplant patients with high-risk factors, effective surveillance methods are required for the early detection of lung cancer.
- Open Access
- 1 July 2019
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 11 (7) , 2939-2944
The technique of intraoperative axillary artery cannulation for extracorporeal membrane oxygenation in lung transplantation
To show our experiences of using the axillary artery with a side graft as a cannulation technique for the inflow of veno-arterial extracorporeal membrane oxygenation (ECMO) in lung transplantation (LTx). This method can avoid complications associated with central and femoral vessel cannulation techniques, and be convenient for the use of intraoperative ECMO into the early postoperative period. Between November 2016 and July 2017, we established intraoperative V/A-ECMO in 32 patients. Among these patients, 5 patients were performed on via axillary artery-percutaneous femoral vein cannulation (15.6%), 2 patients were performed on with veno-venous ECMO (V/V-ECMO) as a bridge to transplantation with hemodynamic instability during transplantation, and additional axillary artery cannulations were performed to establish veno-veno-arterial (V/V/A) ECMO. Mean age was 45.2±10.1 years (range, 26-71 years). In 7 patients undergoing ECMO support during operation, the ECMO was removed in 4 patients immediately after the procedure, 3 patients with "prolonged ECMO" were transferred to the ICU. There were no ECMO-related complications and no patients died. Our protocol for V/A-ECMO cannulation that uses the axillary artery for arterial cannulation provides a safe and improved means for delivering V/A-ECMO support during LTx. Also, it is helpful for prolonging the intraoperative ECMO in the early postoperative period.
- 1 July 2019
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 11 (7) , 2939-2944
Open AccessThe technique of intraoperative axillary artery cannulation for extracorporeal membrane oxygenation in lung transplantation
To show our experiences of using the axillary artery with a side graft as a cannulation technique for the inflow of veno-arterial extracorporeal membrane oxygenation (ECMO) in lung transplantation (LTx). This method can avoid complications associated with central and femoral vessel cannulation techniques, and be convenient for the use of intraoperative ECMO into the early postoperative period. Between November 2016 and July 2017, we established intraoperative V/A-ECMO in 32 patients. Among these patients, 5 patients were performed on via axillary artery-percutaneous femoral vein cannulation (15.6%), 2 patients were performed on with veno-venous ECMO (V/V-ECMO) as a bridge to transplantation with hemodynamic instability during transplantation, and additional axillary artery cannulations were performed to establish veno-veno-arterial (V/V/A) ECMO. Mean age was 45.2±10.1 years (range, 26-71 years). In 7 patients undergoing ECMO support during operation, the ECMO was removed in 4 patients immediately after the procedure, 3 patients with "prolonged ECMO" were transferred to the ICU. There were no ECMO-related complications and no patients died. Our protocol for V/A-ECMO cannulation that uses the axillary artery for arterial cannulation provides a safe and improved means for delivering V/A-ECMO support during LTx. Also, it is helpful for prolonging the intraoperative ECMO in the early postoperative period.